Мы используем Cookies Этот веб-сайт использует cookie-файлы, чтобы предлагать вам наиболее актуальную информацию. Просматривая этот веб-сайт, Вы принимаете cookie-файлы.
In conclusion, further investigation of etoposide in malignant mesothelioma is not recommended.
2
Seric values have been evaluated in 24 patients receiving high doses of etoposide.
3
Patients in group A did not receive either MTX or etoposide.
4
Six patients had been treated with concurrent cisplatin and etoposide plus chest x-ray.
5
One cell line resistant to etoposide-induced apoptosis failed to show degradation of DNA-PKcs.
1
Intravenous and oral etoposide ( VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma.
1
The neoplasm subsequently metastasized and required additional VP-16 and carboplatin for control.
2
Cisplatin and VP-16 combination can be considered as a salvage treatment in heavily pretreated patients with advanced breast cancer.
3
Fas-FasL system participated in the apoptosis induced by DEX and VP-16; different drugs induce apoptosis by different pathway of signal transduction.
4
Chromatin condensation was morphologically evident only when cells detached from the monolayer; untreated or VP-16-treated attached cells retained a normal morphology.
5
This effect was even more pronounced when cells were exposed to VP-16 4 hours before gemcitabine.